The ibogaine medical subculture

被引:114
作者
Alper, Kenneth R. [1 ,2 ]
Lotsof, Howard S. [3 ]
Kaplan, Charles D. [4 ]
机构
[1] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA
[2] NYU, Sch Med, Dept Neurol, New York, NY 10016 USA
[3] Dora Weiner Fdn, Staten Isl, NY 10301 USA
[4] Maastricht Uni, Dept Psychiat & Neuropsychol, NL-6200 MD Maastricht, Netherlands
关键词
ibogaine; iboga alkaloid; substance-related disorders; opioid-related disorders; substance withdrawal; medical ethnography;
D O I
10.1016/j.jep.2007.08.034
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Aim of the study: Ibogaine is a naturally occurring psychoactive indole alkaloid that is used to treat substance-related disorders in a global medical subculture, and is of interest as an ethnopharmacological prototype for experimental investigation and possible rational pharmaceutical development. The subculture is also significant for risks due to the lack of clinical and pharmaceutical standards. This study describes the ibogaine medical subculture and presents quantitative data regarding treatment and the purpose for which individuals have taken ibogaine. Materials and methods: All identified ibogaine "scenes" (defined as a provider in an associated setting) apart from the Bwiti religion in Africa were studied with intensive interviewing, review of the grey literature including the Internet, and the systematic collection of quantitative data. Results: Analysis of ethnographic data yielded a typology of ibogaine scenes, "medical model", "lay provider/treatment guide", "activist/self-help", and "religious/spiritual". An estimated 3414 individuals had taken ibogaine as of February 2006, a fourfold increase relative to 5 years earlier, with 68% of the total having taken it for the treatment of a substance-related disorder, and 53% specifically for opioid withdrawal. Conclusions: Opioid withdrawal is the most common reason for which individuals took ibogaine. The focus on opioid withdrawal in the ibogaine subculture distinguishes ibogaine from other agents commonly termed "psychedelics", and is consistent with experimental research and case series evidence indicating a significant pharmacologically mediated effect of ibogaine in opioid withdrawal. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:9 / 24
页数:16
相关论文
共 147 条
[61]   Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells [J].
Hisaoka, Kazue ;
Takebayashi, Minoru ;
Tsuchioka, Mami ;
Maeda, Natsuko ;
Nakata, Yoshihiro ;
Yamawaki, Shigeto .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (01) :148-157
[62]  
ISBELL H, 1955, AB0491492 CIB, P410
[63]   PRINCIPLES AND PROBLEMS OF PARTICIPANT OBSERVATION [J].
JACKSON, P .
GEOGRAFISKA ANNALER SERIES B-HUMAN GEOGRAPHY, 1983, 65 (01) :39-46
[64]   Extraction studies of Tabernanthe iboga and Voacanga africana [J].
Jenks, CW .
NATURAL PRODUCT LETTERS, 2002, 16 (01) :71-76
[65]   Cytotoxic effects and reversal of multidrug resistance by ibogan and related indole alkaloids [J].
Kam, TS ;
Sim, KM ;
Pang, HS ;
Koyano, T ;
Hayashi, M ;
Komiyama, K .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (17) :4487-4489
[66]  
KLEBER H, 2001, P 1 INT C IB, pR15
[67]   Liquid chromatography-electro spray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood -: Application to a poisoning involving Tabemanthe iboga root [J].
Kontrimaviciute, Violeta ;
Breton, Helene ;
Mathieu, Olivier ;
Mathieu-Daude, Jean-Claude ;
Bressolle, Francoise M. M. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2006, 843 (02) :131-141
[68]   Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub [J].
Kontrimaviciute, Violeta ;
Mathieu, Olivier ;
Mathieu-Daude, Jean-Claude ;
Vainauskas, Paulius ;
Casper, Thierry ;
Baccino, Eric ;
Bressolle, Francoise M. M. .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2006, 30 (07) :434-440
[69]  
Kroupa P., 2005, Maps, V15, P21
[70]  
KROUPA PK, 2006, MIDVOX IBOGAINE LIST